ReviewFrontiers in cellular and infection microbiology2021
Carbapenem-Resistant Enterobacterales in Long-Term Care Facilities: A Global and Narrative Review.
Review in Frontiers in cellular and infection microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 89 citations in OpenAlex.
- Carbapenem-Resistant Enterobacterales (CRE) in Europe: Surveillance Challenges, Emerging Threats and Public Health Preparedness.Antibiotics (Basel, Switzerland) · 2026Review
- Developing Regionally Coordinated Infection Control Strategies for Carbapenem-Resistant and Carbapenemase-Producing Enterobacterales in Acute and Long-Term Care Hospitals: A Delphi Study.Journal of Korean medical science · 2026Article
- Changes in the Epidemiology of Multidrug-Resistant Organisms During the COVID-19 Pandemic: A Six-Year Retrospective Study at a Tertiary Care Hospital in Northeastern Thailand.Medical sciences (Basel, Switzerland) · 2026Observational
- Pre-Target Interception Defines Carbapenem Failure in Carbapenem-Resistant Enterobacterales: A Mechanistic Framework for Spatiotemporal Drug Reprogramming.Pharmaceutics · 2026Review
- Klebsiella pneumoniae Carbapenemase-Producing Enterobacterales Infection and Colonization in a Long-Term Care Facility - Ontario, Canada, May 2024-January 2025.MMWR. Morbidity and mortality weekly report · 2026Article
- Epidemiology and clinical outcomes of carbapenamase-producing organism (CPO) colonization: a tertiary care center experience in Saudi Arabia.BMC infectious diseases · 2026Article
- Incidence and factors associated with carbapenem-resistant Enterobacterales infection among hospitalized internal medicine patients in Korea: a retrospective observational study.Journal of Korean biological nursing science · 2026Article
- Prevalence and risk factors for carbapenem-resistant Enterobacterales colonization in hospitalized children in a provincial hospital in Vietnam.Frontiers in cellular and infection microbiology · 2026Article
- Article
- Characteristics of Notified Carbapenem-resistantJugan geon-gang gwa jilbyeong · 2025Article
- Recurrence, Readmission, and Key Mortality Predictors in Patients with Carbapenem-Resistant Enterobacterales Infections.Diagnostics (Basel, Switzerland) · 2025Article
- Rapid 65-min SYBR-Green PCR Assay for Carbapenem ResistantMicroorganisms · 2025Article
- Diversity in Carbapenemases in Enterobacterales in Southeastern Austria Before and During the COVID-19 Pandemic.Pathogens (Basel, Switzerland) · 2025Article
- Identifying drivers of β-lactam/β-lactamase inhibitor resistance emergence and spread before their clinical deployment.medRxiv : the preprint server for health sciences · 2025Article
- Combating Antimicrobial Resistance: Innovative Strategies Using Peptides, Nanotechnology, Phages,Pharmaceuticals (Basel, Switzerland) · 2025Review
- The emerging concern of IMP variants being resistant to the only IMP-type metallo-β-lactamase inhibitor, xeruborbactam.Antimicrobial agents and chemotherapy · 2025Article
- Article
- Observational
- Clinical evaluation of advanced MALDI-TOF MS for carbapenemase subtyping in Gram-negative isolates.Journal of clinical microbiology · 2025Article
- Unveiling the potential of spirulina algal extract as promising antibacterial and antibiofilm agent against carbapenem-resistant Klebsiella pneumoniae: in vitro and in vivo study.Microbial cell factories · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of carbapenem-resistant Enterobacterales (CRE) has become a major public health concern. Moreover, its colonization among residents of long-term care facilities (LTCFs) is associated with subsequent infections and mortality. To further explore the various aspects concerning CRE in LTCFs, we conducted a literature review on CRE colonization and/or infections in long-term care facilities. The prevalence and incidence of CRE acquisition among residents of LTCFs, especially in California, central Italy, Spain, Japan, and Taiwan, were determined. There was a significant predominance of CRE in LTCFs, especially in high-acuity LTCFs with mechanical ventilation, and thus may serve as outbreak centers. The prevalence rate of CRE in LTCFs was significantly higher than that in acute care settings and the community, which indicated that LTCFs are a vital reservoir for CRE. The detailed species and genomic analyses of CRE among LTCFs reported that
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.